Many gene-therapy strategies under investigation aim to increase the efficacy of current cancer-treatment regimens. Promising results have been obtained in the laboratory and early clinical trials using viral-based motifs specifically designed to enhance the efficacy of ionizing radiation or chemoth
Mechanically enhanced microcapsules for cellular gene therapy
✍ Scribed by F. Shen; M. A. J. Mazumder; N. A. D. Burke; H. D. H. Stöver; M. A. Potter
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 707 KB
- Volume
- 90B
- Category
- Article
- ISSN
- 1552-4973
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Microcapsules bearing a covalently cross‐linked coating have been developed for cellular gene therapy as an improvement on alginate‐poly(L‐lysine)‐alginate (APA) microcapsules that only have ionic cross‐linking. In this study, two mutually reactive polyelectrolytes, a polycation (designated C70), poly([2‐(methacryloyloxy)ethyl]trimethylammonium chloride‐co‐2‐aminoethyl methacrylate hydrochloride) and a polyanion (designated A70), poly(sodium methacrylate‐co‐2‐(methacryloyloxy)ethyl acetoacetate), were used during the microcapsule fabrication. Ca‐alginate beads were sequentially laminated with C70, A70, poly(L‐lysine) (PLL), and alginate. The A70 reacts with both C70 and PLL to form a ∼30 μm thick covalently cross‐linked interpenetrating polymer network on the surface of the capsules. Confocal images confirmed the location of the C70/A70/PLL network and the stability of the network after 4 weeks implantation in mice. The mechanical and chemical resistance of the capsules was tested with a “stress test” where microcapsules were gently shaken in 0.003% EDTA for 15 min. APA capsules disappeared during this treatment, whereas the modified capsules, even those that had been retrieved from mice after 4‐weeks implantation, remained intact. Analysis of solutions passing through model flat membranes showed that the molecular weight cut‐off of alginate‐C70‐A70‐PLL‐alginate is similar to that of alginate‐PLL‐alginate. Recombinant cells encapsulated in APA and modified capsules were able to secrete luciferase into culture media. The modified capsules were found to capture some components of regular culture media used during preparation, causing an immune reaction in implanted mice, but use of UltraCulture serum‐free medium was found to prevent this immune reaction. In vivo biocompatibility of the new capsules was similar to the APA capsules, with no sign of clinical toxicity on complete blood counts and liver function tests. The increased stability of the covalently modified microcapsules coupled with the acceptable biocompatibility and permeability demonstrated their potential for use as immunoisolation devices in gene therapy. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2009
📜 SIMILAR VOLUMES
## Abstract Gene therapy has reached the forefront of studies and research over the last 30 years because of its potential for curing, treating, and preventing diseases associated with DNA mutations. Type 1 and type 2 diabetes are two examples of very common polygenic and multifactorial diseases. T
## Abstract ## Background Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we invest
## Abstract The regulation of gene‐specific activation is critical to the tumor suppressor function by p53. p53 is a well‐characterized transcription factor that responds to DNA damage and other genotoxic stresses by the activation of downstream targets that are involved with repair, differentiatio
## Abstract ## Background Pulmonary delivery of gene therapy offers the potential for the treatment of a range of lung conditions, including cystic fibrosis, asthma and lung cancer. Spray‐drying may be used to prepare dry powders for inhalation; however, aerosolisation of such powders is limited,
## Abstract Reconstruction of bone defects by tissue engineered substitutes requires coordinated coupling between osteogenesis and angiogenesis. Basic fibroblast growth factor (bFGF or FGF‐2) is a protein which acts actively in osteogenesis and angiogenesis during skeletal healing and development.